Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723 is registered in ClinicalTrials.gov with Kardigan, Inc. as lead sponsor.

NCT NCT07210723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07210723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Lead sponsor
Kardigan, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 13, 2026
Completion date
January 31, 2028
Enrollment
332 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic genetic dilated cardiomyopathy